← Back to guidelines
Infectious Disease6 papers

Female tuberculous pelvic inflammatory disease

Last edited: 4/10/2026

Overview

Tuberculous pelvic inflammatory disease (PID) is a form of pelvic inflammatory disease caused by Mycobacterium tuberculosis. It is a less common cause of PID compared to bacterial infections.

Diagnosis

  • Diagnosis can be challenging due to nonspecific symptoms and the rarity of pelvic tuberculosis 1.
  • Diagnostic methods may include:
  • Microscopy and culture of menstrual fluid or endometrial biopsy for Mycobacterium tuberculosis* 1. * Histopathological examination of endometrial biopsy 1. * Tuberculin skin test (TST) or interferon-gamma release assay (IGRA) 1. * Imaging studies such as ultrasound, CT, or MRI may suggest pelvic involvement but are not diagnostic 1.

    Management

  • Management involves a multi-drug anti-tuberculosis regimen, typically for at least six months 1.
  • Standard first-line anti-tuberculosis drugs include isoniazid, rifampicin, pyrazinamide, and ethambutol 1.
  • Surgical intervention may be considered in cases of abscess formation or treatment failure 1.
  • Special Populations

  • Tuberculosis incidence rates show gender differences by age group. In the 15-44 year age group, incidence rates are significantly higher in men (IRR 1.25) 1. The only excess in the female gender was observed in the 10-14 year age group (IRR 0.83) 1.
  • Key Recommendations

  • Treatment of tuberculous PID requires a multi-drug anti-tuberculosis regimen for a minimum of six months 1. (Evidence: Moderate)
  • Standard first-line anti-tuberculosis drugs include isoniazid, rifampicin, pyrazinamide, and ethambutol 1. (Evidence: Moderate)
  • Consider surgical intervention for pelvic tuberculous abscesses or in cases of treatment failure 1. (Evidence: Weak)
  • References

    1 Peer V, Schwartz N, Green MS. Gender differences in tuberculosis incidence rates-A pooled analysis of data from seven high-income countries by age group and time period. Frontiers in public health 2022. link

    Original source

    1. [1]

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG